Dr. Fernando Cabanillas Escalona
Contact Info
Education
- Degree: M.D. University of Puerto Rico School of Medicine, San Juan, Puerto Rico – 1966-1970
- Degree: BS University of Puerto Rico (biology major) Río Piedras, PR. – 1963-1966
INTERNSHIP & RESIDENCY:
- University District Hospital, Puerto Rico, Internal Medicine – July 1970 – June 1973-
FELLOWSHIP:
- University District Hospital, Puerto Rico, Hematology – July 1973 – June 1974
- The University of Texas System Cancer Center, M. D. Anderson Hospital, Department of
- Developmental Therapeutics, Two-Year Fellowship in Medical Oncology – July 1974 – June 1976
ACADEMIC POSITIONS
Professor of Medicine: University of Puerto Rico, School of Medicine
Adjunct Professor of Medicine: The University of Texas, M. D. Anderson Cancer Center
Adjunct Professor of Medicine, Moffitt Cancer Center, Tampa, Florida
Faculty Associate, Department of Developmental Therapeutics, M. D. Anderson Hospital – July 1976 – June 1977
Assistant Internist and Assistant Professor of Medicine, Department of Developmental Therapeutics, M. D. Anderson Hospital – 1977 –1978
Associate Internist and Assistant Professor of Medicine, Department of Developmental Therapeutics, M.D. Anderson Hospital – 1978 –1980
Associate Internist and Associate Professor of Medicine, Department of Developmental Therapeutics, M. D. Anderson Hospital 1980 –1983
Internist and Associate Professor of Medicine, Department of Hematology, M. D. Anderson Hospital -1983-1986
Internist and Professor of Medicine, Department of Lymphoma/Myeloma, M. D., Anderson Hospital 1986-2002
Adjunct Professor of Medicine, MD Anderson Hospital
Medical Director Auxilio Mutuo Cancer Center – 2002-2018
February 2009 – to present Professor of Medicine, UPR School of Medicine
August 2009 – to present Adjunct Professor of Medicine, Moffitt Cancer Center
ACADEMIC ADMINISTRATIVE APPOINTMENTS:
Chief, Lymphoma/Myeloma Section, MD Anderson – 1984-1997
Chairman, Department of Lymphoma/Myeloma, MD Anderson 1998- 2002
Chairman, Centro de Cancer Auxilio Mutuo, Hospital Español Auxilio Mutuo de Puerto Rico 2002-present
RESEARCH INTEREST
Schering Corp. Fund for Research in Hodgkin’s Disease.
University Cancer Foundation- “Monitoring Therapy of Low Grade Lymphoma by PCR” (1/5/93-1/4/94).
E.I. Dupont- “A Phase II Clinical Trial to Evaluate the Safety and
Efficacy of a Single Weekly Schedule of Administration of Brequinar Sodium (DuP 785) in Cancer Patients with Refractory Lymphoma or Chronic Lymphocytic Leukemia” (DM89-057).
NCI – Co-Investigator, “Role of Human Retroviruses in Human AIDSRelated Lymphomas” (CA52778; R. Ford-P.I.; 7/1/90 – 6/30/93).
Adria Laboratories- “Idarubicin Study” (DM91-004/DM90-115/DM91033; 1/1/92-2/28/94).
IDEC Pharmaceuticals Corp.- “A Phase II Study of Anti-Idiotype Antibody for the Treatment of Recurrent B-Cell Lymphomas” (DM91054; 8/1/91-1/31/95).
NCI – Co-Investigator, “Minimal Residual Disease in Lymphomas With the t(14;18)” (RO1 CA49443-03; M.S. Lee-P.I.; 4/1/89 – 3/31/94).
Berlex Laboratories- “Intensive vs. Milder Therapy for Stage IV Low
Grade Follicular Lymphomas Monitored by Polymerase Chain Reaction Technique” (DM92-103; 2/5/94-2/4/95)
NCI Interactive RO1 (total award for 4 years= $2,328,226.) Coordinator, “Monitoring Therapy of Low Grade Lymphoma by PCR” (RO1 CA62518; F. Cabanillas-P.I.-Project 1; 9/1/93 – 6/30/98)
Schering Corp.- “STUDIES WITH GM-CSF” (DM92-053/DM92-054; 9/1/94 – 2/28/95)
Bristol-Myers Squibb Company- “Phase I Taxol” (DM93-098; 9/12/94 – 8/31/95)